Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 7 for:    aquestive

Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03179891
Recruitment Status : Completed
First Posted : June 7, 2017
Results First Posted : September 18, 2020
Last Update Posted : September 18, 2020
Sponsor:
Collaborators:
inVentiv Health Clinical
Covance
Information provided by (Responsible Party):
Aquestive Therapeutics

Tracking Information
First Submitted Date  ICMJE May 26, 2017
First Posted Date  ICMJE June 7, 2017
Results First Submitted Date  ICMJE June 24, 2020
Results First Posted Date  ICMJE September 18, 2020
Last Update Posted Date September 18, 2020
Actual Study Start Date  ICMJE May 25, 2017
Actual Primary Completion Date July 25, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
  • Tmax Pharmacokinetic EndPoints [ Time Frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours ]
    Observed time to reach maximum drug concentration (Tmax)
  • Cmax Pharmacokinetic EndPoints [ Time Frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours ]
    Observed Peak Drug Concentration (Cmax)
  • Area Under the Plasma Concentration Curve Pharmacokinetic EndPoints [ Time Frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours ]
    Area under the Plasma Concentration -time curve from time zero until the last measured time (AUC0-t)
Original Primary Outcome Measures  ICMJE
 (submitted: June 6, 2017)
  • Tmax Pharmacokinetic EndPoints [ Time Frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours ]
    Observed time to reach maximum drug concentration (Tmax)
  • Cmax Pharmacokinetic EndPoints [ Time Frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours ]
    Observed Peak Drug Concentration (Cmax)
  • Area under the Plasma Concentration curve Pharmacokinetic EndPoints [ Time Frame: -2 to 0, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, 144, 192, 240 hours ]
    Area under the Plasma Concentration -time curve from time zero until the last measured time (AUC0-t) (Period A only)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 27, 2020)
  • Usability Endpoint - Successful Insertion/Placement of the Diazepam Buccal Film (DBF) on First Attempt [ Time Frame: Subject was observed for 15 minutes after initial film placement/adhesion ]
    Number of subjects with unsuccessful insertion/placement of the DBF on first attempt at administration Number of subjects with successful insertion/placement of the DBF on first attempt at administration Placement is judged to be successful when film adheres to the center of buccal mucosa of either right or left cheek. Unsuccessful placements were followed by a subsequent successful insertion/placement of DBF
  • Usability Endpoint: Swallowing the Film Before Complete Disintegration/Dissolution [ Time Frame: Subject was observed for 15 minutes immediately following DBF placement/adhesion ]
    Was the film noted to have been swallowed by the subject ? Yes No Subjects were instructed to swallow any remnants of film still present in oral cavity 15 minutes after initial film placement. Results include subjects who swallowed film at any point during the 15 minutes immediately after initial film placement.
  • Usability Endpoint: Retention of Diazepam Buccal Film (DBF) From Placement to Complete Disintegration [ Time Frame: Subject was observed for 15 minutes immediately following DBF placement/adhesion ]
    Was the DBF spit out or blown out by the subject after placement on buccal mucosa or did the subject chew, talk, or move the DBF prior to complete disintegration/dissolution? Yes No
  • Usability Endpoint: Exit of Saliva During the Time the Diazepam Buccal Film (DBF) Was Adhered to Buccal Mucosa [ Time Frame: Subject was observed for 15 minutes immediately following DBF placement/adhesion ]
    The observer documented if any saliva was seen to exit the mouth during the time the DBF was adhered to buccal mucosa
  • Usability Endpoint: Amount of Saliva That Exited the Mouth After Film Placement [ Time Frame: Subject was observed for 15 minutes immediately following DBF placement/adhesion ]
    If Yes - saliva exited the mouth during the time, estimate in milliliters of the amount of saliva that exited the mouth after DBF placement on the buccal surface
Original Secondary Outcome Measures  ICMJE
 (submitted: June 6, 2017)
  • Usability Endpoint - Successful insertion [ Time Frame: 0.167, 0.5 and 1 hours ]
    Number of successful attempts to insert the DBSF
  • Usability Endpoint - Swallowing [ Time Frame: 0.167, 0.5 and 1 hours ]
    Number of times the DBSF is swallowed prior to dissolution
  • Usability Endpoint - Lack of adherence [ Time Frame: 0.167, 0.5 and 1 hours ]
    Number of times the DBSF is spit out or blown out by patient after adherence to buccal mucosa
  • Usability Endpoint - Saliva exiting the mouth [ Time Frame: 0.167, 0.5 and 1 hours ]
    Number of times saliva exits the mouth
  • Usability Endpoint - Amount of saliva exiting the mouth [ Time Frame: 0.167, 0.5 and 1 hours ]
    The amount of saliva exiting the mouth
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy
Official Title  ICMJE A Multicenter, Open Label, Crossover Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Brief Summary This Phase 2 open-label, two-way study was conducted in adult subjects with epilepsy who were on stable regimens of anti-epileptic drugs (AEDs) and who were admitted to an Epilepsy Monitoring Unit (EMU), General Clinical Research Center (GCRC), or similar facility for evaluation of their seizures. All subjects received a single DBF 12.5 mg dose during the Interictal State and a single DBF 12.5 mg dose during the Ictal/peri-ictal state with at least 14 days washout between the 2 doses.
Detailed Description

This was a Phase 2 multicenter, open-label, two-way study conducted in adult subjects to assess the bioavailability, pharmacokinetics, and safety of DBF during the Interictal Period and during the Ictal/peri-ictal Period, with a minimum of 14 days of washout between periods. Subjects had a clinical diagnosis of epilepsy (with generalized tonic-clonic seizures or focal seizures with impaired awareness) who were on stable regimens of anti-epileptic drugs and were scheduled for admission to an EMU, GCRC, or similar facility for evaluation.

All subjects were to receive a single 12.5-mg dose of study drug, without regard to meals, during both Interictal Period and Ictal/peri-ictal Period. The treatment was identical for both periods. Treatment sequence was not randomized. The interictal period and ictal/peri-ictal could occur in either order as determined by seizure occurrence.

Interictal Period: Subjects were considered to be in an interictal state if an interval of at least 3 hours had elapsed since any clinically observable postictal signs or symptoms (from the last observed seizure) and the subject had been seizure-free over this period. Subjects on electroencephalogram (EEG) video monitoring were to be considered to be in an interictal state if an interval of at least 3 hours had elapsed since there were any postictal electrical findings on EEG.

Ictal/peri-ictal Period: For the purposes of this study, the ictal state was defined as an ongoing clinically observable seizure or seizure activity as verified via EEG. The periictal state was defined clinically as the subject's immediate postictal state following a generalized tonic-clonic (GTC) seizure or focal seizure with impaired awareness, and within 5 minutes following the last clonic jerk. For subjects on EEG video monitoring, the periictal state was to be defined as less than 5 minutes after cessation of seizure activity as verified via EEG.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
This was a multicenter, open-label study comprised of 2 treatment periods with a minimum 14 days washout between the 2 treatment periods.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Epilepsy
Intervention  ICMJE Drug: Diazepam Buccal Film 12.5 mg
All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
Other Name: DBF 12.5mg
Study Arms  ICMJE
  • Experimental: Interictal Period
    All subjects received 12.5 mg DBF during the interictal state.
    Intervention: Drug: Diazepam Buccal Film 12.5 mg
  • Experimental: Ictal/Peri-ictal Period
    All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
    Intervention: Drug: Diazepam Buccal Film 12.5 mg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 24, 2020)
35
Original Estimated Enrollment  ICMJE
 (submitted: June 6, 2017)
40
Actual Study Completion Date  ICMJE December 21, 2018
Actual Primary Completion Date July 25, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Potential subjects meeting all of the following criteria may be included in the study:

  1. Subjects scheduled for admission to the institution's EMU, GCRC (General Clinical Research Center) or similar facility for evaluation within 28 days.
  2. Male and female subjects between 18 to 65 years of age, inclusive.
  3. Subjects having a body weight of ≥ 40 kg to 111 kg.
  4. Subjects have a clinical diagnosis of epilepsy and are scheduled to be admitted to an Epilepsy Monitoring Unit (EMU) for extracranial video-Electroencephalogram (EEG) recording of a seizure event for evaluation of their epilepsy.
  5. Subjects have an average frequency of > 1 seizure every 3 days or > 10 seizures / month as documented by seizure diaries dispensed at the Screening Visit and verified prior to initiation of Period A or Period B.
  6. Female subjects have a negative serum pregnancy test at Screening. Female subjects of childbearing potential (i.e., not surgically sterile or 2 years postmenopausal) must have a negative pregnancy test at screening and a partner who is sterile, agree to abstinence, be practicing double barrier contraception or using an FDA approved contraceptive (e.g., licensed hormonal or barrier methods) for greater than 2 months prior to screening visit and commit to an acceptable form of birth control for the duration of the study and for 30 days after participation in the study.
  7. Subjects are currently receiving at least one antiepileptic medication.
  8. Subjects or subject's legally authorized representative (LAR) must be willing and able to complete informed consent/assent and HIPAA authorization.
  9. Subjects must agree and must be willing to comply with all required study procedures while in the EMU or GCRC.
  10. Ability to comprehend and be informed of the nature of the study, as assessed by the PI or Sub-Investigator.
  11. Ability to consume standard meals.
  12. Availability to volunteer for the entire study duration and willing to adhere to all protocol requirements.

Exclusion Criteria:

Potential subjects meeting any of the following criteria will be excluded:

  1. Subjects having a progressive neurological disorder such as brain tumor, demyelinating disease, or degenerative central nervous system (CNS) disease that is likely to progress in the next 12 months.
  2. Subjects having respiratory failure (or is at risk for respiratory failure) or other severe cardiorespiratory disease with New York Heart Association Class III or IV functional status, or requires supplemental oxygen.
  3. Female subjects who are lactating or positive serum pregnancy test (ß-hCG) at screening for female subjects ≥12 years of age.
  4. Subjects with severe psychiatric disease that in the Investigator's judgment would prevent the patient's successful completion of the study.
  5. Subjects who have an episode of status epilepticus, as determined by the Principal Investigator/Sub-Investigator, at any time during Period B (EMU, GCRC or similar facility Visit
  6. Subjects with known history or presence of any clinically significant hepatic (e.g. hepatic impairment), renal/genitourinary (renal impairment, kidney stones), psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the Principal Investigator/Sub-Investigator and confirmed by Sponsor via written communication prior to subject enrollment.
  7. Subjects with any clinically significant illness other than epilepsy within 30 days prior to first dosing, as determined by the Principal Investigator/Sub-Investigator.
  8. Subjects with any significant physical or organ abnormality as determined by the Principal Investigator/Sub-Investigator.
  9. Subjects with any significant lesion of the oral cavity or having oral prophylactic procedures within 30 days prior to first dosing.
  10. Subjects with a QTc interval QTcF>450 msec for males and QTcF>470 msec for females on screening ECG, unless determined as not clinically significant by the Investigator.
  11. Subjects with a positive test result for any of the following: drugs of abuse (amphetamines, cocaine, opiates, or phencyclidine), a positive breath alcohol test.
  12. Subjects with a known history or presence of: a. Alcohol abuse or dependence within one year prior to first drug administration; b. Drug abuse or dependence; c. Hypersensitivity or idiosyncratic reaction to diazepam, its excipients, sodium phosphates; and/or related substances, e.g. benzodiazepines; d. Glaucoma (open or acute narrow angle); e. Severe allergic reactions (e.g. anaphylactic reactions, angioedema
  13. Subjects who have participated in another clinical trial or who received an investigational drug within 30 days prior to first drug administration or 5 half-lives of the investigational drug-whichever is the longer period.
  14. Blood or plasma donation within 30 days prior to Screening
  15. Subjects not willing or unable to tolerate blood draws.
  16. Subjects who have received any other dosage form of diazepam or benzodiazepines within 2 weeks prior to entering Period A or Period B.
  17. Consumption of alcohol within 48 hours before dosing and food or beverages containing grapefruit, star fruit, Seville oranges, and/or pomelo or their derived products (e.g., fruit juice) within 10 days prior to first drug administration.
  18. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (e.g. cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, or HIV antivirals) and strong inducers of CYP enzymes (e.g. glucocorticoids, St. John´s Wort, or rifampicin) in the previous 30 days before first drug administration [barbiturates, carbamazepine, and phenytoin are allowed since these are common AEDs (Anti-epileptic drugs)].
  19. Use of any monoamine oxidase (MAO) inhibitors (e.g. phenelzine, tranylcypromine), phenothiazines (chlorpromazine) within 30 days prior to first drug administration.
  20. Employee or immediate relative of an employee of the investigator, MonoSol Rx LLC, any of its affiliates or partners, or inVentiv Health.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03179891
Other Study ID Numbers  ICMJE 160326
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Aquestive Therapeutics
Study Sponsor  ICMJE Aquestive Therapeutics
Collaborators  ICMJE
  • inVentiv Health Clinical
  • Covance
Investigators  ICMJE
Study Director: Gary Slatko Aquestive Therapeutics
PRS Account Aquestive Therapeutics
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP